The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

BridgeBio Pharma (BBIO) announced the Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...

BridgeBio Pharma (BBIO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization in the European Union for acoramidis for ...

The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.

The office of Senate Majority Leader Chuck Schumer (D-N.Y.) said that this week he will bring the HEARTS Act, the bipartisan ...

Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations ...

The new understanding of molecular events that drive the various forms of amyloidosis has generated treatment strategies that ...

Today's news roundup includes a European Union project aimed at accelerating digital health adoption across the North Sea region.

This week, the FDA issued recommendations for streamlining the clearance process for AI-powered medical devices. The memo announcing this change recognizes that the utilization of AI in devices “is an ...